WHO ICTRP trial
Modafinil In Debilitating Fatigue After Stroke 2 (MIDAS 2)
ACTRN12618000602224 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12618000602224 |
|---|---|
| Public title | Modafinil In Debilitating Fatigue After Stroke 2 (MIDAS 2) |
| Scientific title | A Phase III, Multicentre, Prospective, Randomised, Placebo-controlled, Double-blind, Parallel group study to evaluate the effect of Modafinil on Debilitating Fatigue in Stroke Survivors |
| Primary sponsor | The Florey Institute of Neuroscience and Mental Health (The Florey) |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | Australia |
| Conditions | Post Stroke Fatigue; Post Stroke Fatigue;Stroke - Haemorrhagic;Stroke - Ischaemic |
| Interventions | Study Drug: Modafinil Dose: 200mg taken once a day for 56 days followed by open-label non-randomised observational phase for 10 months. Route: oral tablet Time of administration; Modafinil is ideally to be taken with breakfast. Treatment… |
| Registration date | Apr 18, 2018 |
| Target size | 300 |
| Secondary IDs | Nil |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: